⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SYRE News
Spyre Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
SYRE
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
globenewswire.com
SYRE
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
globenewswire.com
SYRE
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Form 8-K
sec.gov
SYRE
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
globenewswire.com
SYRE
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
globenewswire.com
SYRE
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE